Dr. Pushkar Kulkarni

  • Designation :Senior Research Scientist
  • Department :Center for Innovation in Molecular and Pharmaceutical Sciences (CIMPS)
  • Affiliation :Dr. Reddy Institute of Life Sciences
  • Email Id :pushkark@drils.org
  • Web Url : https://www.drils.org/cimps.php?menu=2


Research Interest

The major objective of our laboratory is to develop and validate zebrafish models of pharmacology and toxicology. Another important objective is to identify the relevance and translatability to human and animal pharmaceutical research.

Towards this objective, we are working on the following:
  • Nanotoxicology  Standardized assays for Hepatotoxicity, Arrhythmogenecity, Nephrotoxicity and Teratogenecity for nanotherapeutics  Funded by DBT Nanobiotechnology Task Force. Publications under review.
  • ECG for QT liability assessment
  • EEG for Seizure liability assessment 
Pharmacology Assays: 
  • Autism Spectrum Disorders 
  • Multiple Sclerosis 
  • Epilepsy 
  • Anxiety 
  • Depression
  • Angiogenesis
  • Xenograft 
Gene knock-out models for Rare Diseases (filed patent on new platform): 
  • Fragile X Syndrome (FXS) 
  • Glutaric aciduria type 1 (GA1) 
  • Gaucher's disease (GD)
  • Duchenne muscular dystrophy (DMD)